Abstract 2291P
Background
Desirable features for successful ACT include effective migration into tumors, overcoming immunosuppression and dearth of nutrients to survive/function within the tumor microenvironment (TME), not restricted by antigen exclusivity, impervious to antigen escape, and engages the recipient’s immune system. WU-NK-101 (WUNK) is a non-engineered cytokine-reprogrammed, expanded, cryopreserved, off-the-shelf NK cell product derived from PBMCs. We have previously shown that WUNK traffic to, and persist in tumor models, and enhanced by mAb combination. Additionally, compared to conventional NK (cNK), WUNK demonstrated improved cytotoxicity A549 (NSCLC): 0% vs. 79%, p=0.0001 and LoVo (CRC) 0% vs. 57%, p=0.01, respectively]. (Rutella et al., ESMO 2022).
Methods
Cell phenotypes were evaluated by flow cytometry. Fluorescent Abs for CD3, CD56 were used to resolve BM architecture.
Results
Compared to cNK, WUNK expresses higher levels of cell surface nutrient transporters which adapted to the differing TMEs, suggesting metabolic fitness, and flexibility. Unlike cNK and T-cells, WUNK cytotoxic activity was preserved in TME-aligned media (WUNK: 96.5% vs. 88.2%, p=0.45; cNK: 44.1% vs. 13.5%, p=0.009; T-cell: 53.2 % vs.25.2%, p=0.041, TME vs. conventional media, respectively). Resistance to TME was further confirmed in native-TME-aligned 3D assays from primary tumor surgical samples. WUNK was effective in lysing malignant cells, while sparing benign cells, indicating that WUNK are not indiscriminate killers. This suggests lack of antigen exclusivity and portends resistance to antigen escape. Treatment with memory-NK cells led to T-cell infiltration and co-localization within TME, suggesting coordination with endogenous immune cells. Synergy of WUNK with the endogenous immune system was also documented in a humanized mouse (engrafted with hPBMCs) model, across a number of ST xenografts, which showed deeper anti-tumor responses.
Conclusions
We show that WUNK cells exhibit features that overcome challenges for ACT and enhances anti-tumor activity in ST, heralding the promise of NK cell therapy for ST. The data presented augurs positively for pts to be treated in the upcoming phase I/b clinical study.
Clinical trial identification
NCT# 05674526.
Editorial acknowledgement
Legal entity responsible for the study
Wugen.
Funding
Wugen.
Disclosure
J. Muth, T. Leedom, K. Magee, B. Muz, J. Davidson-Moncada: Financial Interests, Personal, Stocks/Shares: Wugen. V. Petit: Financial Interests, Personal, Stocks or ownership: Metafora. M. Berrien-Elliott, T.A. Fehniger: Financial Interests, Personal, Stocks or ownership: Wugen. S. Rutella: Financial Interests, Institutional, Research Funding: Wugen. All other authors have declared no conflicts of interest.
Resources from the same session
2305P - Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
Presenter: Sejin Kim
Session: Poster session 08
2306P - How TAILORx changed treatment allocation based on 21-gene recurrence score in the daily clinic: A single center retrospective analysis
Presenter: Elena Chiru
Session: Poster session 08
2307P - Loss of CYP2D6 activity sensitizes liver cancer cells to chemotherapy
Presenter: Natallia Rameika
Session: Poster session 08
2308P - CyPep-1 reprograms the tumor microenvironment and enhances the efficacy of immune checkpoint inhibitors
Presenter: Bassam Janji
Session: Poster session 08
2309P - High DDR1 mRNA and protein expression across human tumor types correlate with epithelial composition of the tumor microenvironment
Presenter: Laura Dillon
Session: Poster session 08
2310P - Oxygen nano-bubbles attenuate hypoxia-induced tumour malignancy in tumour xenograft models
Presenter: Kumari Bhavya
Session: Poster session 08
2311P - Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA4
Presenter: Dongwoo Chae
Session: Poster session 08
2312P - SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity
Presenter: Annamaria Bonelli
Session: Poster session 08
2313P - APOBEC mutagenesis and macrophage infiltration in cancer
Presenter: Andrea Gazzo
Session: Poster session 08
2314P - Quality and safety of research biopsies (RB) in oncology clinical trials
Presenter: Paolo Nuciforo
Session: Poster session 08